AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
Live video webcast on Wednesday, January 18th at 11:00 AM ETOCALA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
Clinical Trial
TCR² Therapeutics Announces Pipeline Priorities for 2023
gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data expected in 2H 2023Second-generation...
Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences
Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater ChinaWARREN, N.J.,...
IMUNON Enters into Collaborative Research Agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company,...
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
-- Breakthrough Therapy Designation for 24-Valent Investigational Pneumococcal Conjugate Vaccine Candidate Based on Positive Topline Proof-of-Concept Data Results in Adults...
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
Nexalin Technology CEO Provides Letter to Shareholders
HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today provided the...
Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on...
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
SIOUX FALLS, S.D., Jan. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel...
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
– Final cohort of Phase 1 study projected to be complete in H1 2023 – – Phase 2-enabling GLP toxicology...
ORYZON to Give Updates on Corporate Progress in January
6th Sachs Annual Neuroscience Innovation Forum12th Annual LifeSci Advisors Corporate Access Event41st Annual J.P. Morgan Healthcare ConferenceInvest Securities Biomed Forum...
Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
NORCROSS, Ga., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...
Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Allergic Disease
Topline data anticipated in Q2 2023NEW ORLEANS and LOS ANGELES and LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics...
Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
New round of financing led by Vensana Capital will support technology platform expansion and further validating VX1, Volta’s Artificial Intelligence...
Noema Pharma to Attend and Present at 41st Annual J.P. Morgan Healthcare Conference in San Francisco
BASEL, Switzerland and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous...
AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma
AUM302 is potentially eligible to receive a rare pediatric disease priority review voucher at the time of marketing approvalSINGAPORE and...
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™...
Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders
Expands intellectual property portfolio with composition-of-matter patent protection for second novel molecular glue Protein degrader intellectual property portfolio now includes...
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219
COVALENT-111, now underway in the US, has completed Phase I and is currently enrolling type 2 diabetes patients in the Phase...
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...